Steroids reduced misleading spinal cord shrinkage in MS
Key Takeaway
In newly diagnosed MS, high-dose steroids before the first scan were linked to less misleading spinal cord shrinkage after treatment began.
What They Found
Researchers tracked spinal cord scans in people newly diagnosed with MS. Some received high-dose steroids before their first scan, and some did not. Among those starting MS treatment, people without earlier steroids showed more spinal cord shrinkage in year one than year two. That early pattern was not seen in those who had received steroids. The researchers describe this early change as apparent shrinkage caused by fading inflammation, rather than tissue loss alone.
Who Should Care and Why
The study followed people with newly diagnosed relapsing-remitting MS who had not yet started ongoing MS treatment. Its findings concern how doctors interpret spinal cord scans soon after treatment starts. Earlier steroid use was linked to a smaller early change on those scans. That difference may matter when scans are used to measure changes in MS over time. The study did not assess whether steroids improved symptoms or prevented disability.
Important Considerations
You should know this study followed 123 people for up to three years. You should also know the researchers compared groups based on treatment they had received; they did not assign treatments at random. These findings do not show that steroids prevented lasting spinal cord damage.
AI-generated summary — for informational purposes only, not medical advice
Categories:
You May Also Like
11/1/2026
Researchers compared blood from people with childhood-onset MS and healthy volunteers. They found DN
Read More
11/1/2026
In 24 people with severe MS, stem cell treatment lowered signs of inflammation and nerve damage for
Read More
11/1/2026
A review of 49 studies finds special brain scans can detect MS-related inflammation, but scan method
Read More
10/6/2026
Researchers found immune cells that swap surface tags in MS. An MS treatment removed them in the stu
Read More
10/6/2026
In children with MS, immune attacks on the brain and spinal cord may go unchecked. See what research
Read More
10/5/2026
A 10-year MS study found that starting ocrelizumab early helped protect movement and reduce relapses
Read MoreUnderstanding MS Research
Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.